What Weight Do You Need to Be for Mounjaro?

What the clinical evidence and the MHRA licence actually say about weight thresholds

Mounjaro's UK licence is built on the evidence from the SURMOUNT clinical programme. In SURMOUNT-1, the largest of those trials, adults with a BMI of 30 or above (or 27 or above with a weight-related condition) were enrolled. Tirzepatide produced average body-weight reductions of around 20% at the highest dose over 72 weeks, making it the most effective licensed weight-loss medicine in the UK at the time NICE appraised it, though if you are considering how it compares to older options, our breakdown of Xenical vs Mounjaro puts the two treatments side by side. The MHRA granted the licence on the basis of that data, and the resulting BMI thresholds are now the legal minimum for prescribing.

In practice this means two distinct entry points. A BMI of 30 or above qualifies you regardless of other conditions. A BMI between 27 and 29.9 qualifies you only if a prescriber confirms at least one weight-related comorbidity, common examples include prediabetes, obstructive sleep apnoea, osteoarthritis and raised cardiovascular risk. You can get a sense of where you stand using the NHS BMI calculator before you consult anyone.

One important nuance: UK clinical guidance recognises that health risks associated with excess weight occur at lower BMI values in people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. The standard thresholds are reduced by 2.5 kg/m² for these groups, meaning a BMI of 27.5 or above (unconditional) or 24.5 or above with a qualifying condition can be sufficient. A prescriber will apply the relevant threshold based on your background.

How the NHS draws the line differently from private prescribers

NICE's technology appraisal of tirzepatide (TA1026) sets out a more restrictive eligibility framework for NHS-funded access. As of summer 2026, the NHS is rolling out Mounjaro in phases. The first cohort (active from June 2025) requires a BMI of 40 or above alongside four or more specific conditions from a defined list (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes). A second cohort, activated in June 2026, covers adults with a BMI between 35 and 39.9 who also have four or more of those conditions.

That phased approach is deliberately narrow. It reflects both NHS capacity and cost-effectiveness modelling, not a clinical judgement that lower-BMI patients don't benefit. Many people who would gain from treatment simply don't meet the NHS thresholds yet, or face waits that can stretch to months or longer depending on their area. Our Mounjaro overview explains how private prescribing works as an alternative route for those who are eligible under the licensed criteria but not the NHS ones.

If cost is a consideration when thinking about going private, our guide to Mounjaro costs in the UK sets out what private treatment typically includes and what to look for in a provider.

What matters beyond the number on the scales

The BMI thresholds are a starting gate, not a guarantee of a prescription. A prescriber reviewing your consultation will also consider your medical history, any contraindications, and which medicines you currently take. Mounjaro is not recommended during pregnancy, and women using oral contraceptives should discuss adding a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, since gastric-emptying changes can affect how well the pill is absorbed. The NHS England guidance on weight-management injections covers this and other practical considerations clearly.

There are also conditions that require careful discussion before prescribing, a personal or family history of medullary thyroid cancer, certain pancreatic conditions, and some gastrointestinal disorders among them. That is precisely why the consultation exists: to surface anything that might change the clinical picture. A reading of your BMI at 7pm on your phone tells you one number. A prescriber's assessment tells you whether treatment is genuinely appropriate for you. Those are different questions.

It is also worth noting that Mounjaro and semaglutide work differently at a receptor level, tirzepatide activates both GIP and GLP-1 pathways, while semaglutide targets GLP-1 alone. If you are weighing up which medicine might suit you better, the comparison on our tirzepatide versus Mounjaro page sets out what the evidence actually shows. And if you'd like to understand the minimum threshold in more granular terms, our minimum weight for Mounjaro page goes into further detail.

Age matters too: Mounjaro is only licensed for adults (18 and over). If you are wondering about the age requirements for Mounjaro, that page answers the question precisely.

When you are ready to explore whether treatment is right for you, speak to our prescribers through a free consultation, reviewed the same day by a real clinician, with no waiting list.